Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Phase 1

Completed

Conditions: Rhabdomyosarcoma
Astrocytoma
Hepatoblastoma
Glioma
Medulloblastoma
Neuroblastoma

Interventions: Drug: LDE225

First Posted Date: 2010-05-18

Last Posted Date: 2017-03-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT01125800

Locations: 🇺🇸
Seattle Children's Hospital CPKC412A2114, Seattle, Washington, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. John Hopkins, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute DFCI (3), Boston, Massachusetts, United States

and more 2 locations

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

Phase 2

Completed

Conditions: Non-small-cell Lung Cancer

Interventions: Drug: AUY922

First Posted Date: 2010-05-17

Last Posted Date: 2016-03-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 153

Registration Number: NCT01124864

Locations: 🇺🇸
University of California at Los Angeles UCLA - Santa Monica, Los Angeles, California, United States
🇺🇸
St. Luke's Hospital and Health Network St Luke's, Bethlehem, Pennsylvania, United States
🇺🇸
Dana Farber Cancer Institute DFCI, Boston, Massachusetts, United States

and more 2 locations

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: QVA149
Drug: NVA237
Drug: tiotropium
Drug: Salbutamol/albuterol

First Posted Date: 2010-05-11

Last Posted Date: 2013-12-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2224

Registration Number: NCT01120691

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

A Study to Assess the Long-term Safety of QVA149

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: QVA149
Drug: Placebo

First Posted Date: 2010-05-11

Last Posted Date: 2013-01-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 339

Registration Number: NCT01120717

Locations: 🇬🇧
Novartis Investigative Site, Wellingborough, United Kingdom

Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: NVA237
Drug: Tiotropium

First Posted Date: 2010-05-10

Last Posted Date: 2013-01-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 211

Registration Number: NCT01119937

Locations: 🇯🇵
Novartis Investigative Site, Saitama, Japan

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: NVA237 25.0 µg once daily
Drug: Placebo to NVA237 once daily
Drug: NVA237 12.5 µg once daily
Drug: NVA237 25.0 µg twice daily
Drug: NVA237 50.0 µg twice daily
Drug: NVA237 12.5 µg twice daily
Drug: NVA237 100.0 µg once daily
Drug: NVA237 50.0 µg once daily

First Posted Date: 2010-05-10

Last Posted Date: 2015-03-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 388

Registration Number: NCT01119950

Locations: 🇧🇪
Novartis Investigative site, Jambes, Belgium
🇪🇸
Novartis Investigative Site, Ponferrada, Spain

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Phase 3

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Imatinib
Drug: Placebo

First Posted Date: 2010-05-06

Last Posted Date: 2015-08-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 144

Registration Number: NCT01117987

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients

Phase 3

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Everolimus
Drug: Prograf or Neoral

First Posted Date: 2010-05-03

Last Posted Date: 2017-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 828

Registration Number: NCT01114529

Locations: 🇹🇷
Novartis Investigative Site, Istanbul, Turkey

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Agomelatine (AGO178C)
Drug: Placebo

First Posted Date: 2010-04-27

Last Posted Date: 2020-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 589

Registration Number: NCT01110902

Locations: 🇺🇸
CRI Worldwide, LLC - Lourdes Division, Willingboro, New Jersey, United States
🇺🇸
Medical University of South Carolina, North Charleston, South Carolina, United States
🇺🇸
SP Research, Oklahoma City, Oklahoma, United States

and more 42 locations

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor

Interventions: Drug: Nilotinib

First Posted Date: 2010-04-27

Last Posted Date: 2017-02-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2

Registration Number: NCT01110668

Locations: 🇹🇷
Novartis Investigative Site, Izmir, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy